Poliovirus vaccine inactivated - Biologic Drug Details

Summary for poliovirus vaccine inactivated

Tradenames:	1
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2

Pharmacology for poliovirus vaccine inactivated

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Poliovirus Vaccine
Chemical Structure	Poliovirus Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for poliovirus vaccine inactivated Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for poliovirus vaccine inactivated Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for poliovirus vaccine inactivated Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Inactivated Poliovirus Vaccine (IPV)

Last updated: February 14, 2026

What is the Current Market Size for IPV?

The global inactivated poliovirus vaccine market reached approximately $1.1 billion in 2022. The market expands at a compound annual growth rate (CAGR) of 4.8% from 2023 to 2030, driven by increased vaccination efforts worldwide.

Led by regions such as North America, Europe, and Asia-Pacific, vaccination programs target both endemic and non-endemic areas. The global push to eradicate polio maintains vaccine demand, especially as new immunization schedules incorporate IPV.

How Do Market Factors Influence Growth?

Regulatory Environment

The WHO recommends IPV as part of the routine immunization schedule, replacing oral poliovirus vaccine (OPV) in many countries. Regulatory agencies, including FDA and EMA, approve IPV formulations with strict safety and efficacy standards. The accelerated approval of fractional doses—administered intradermally—has expanded vaccination options.

Supply Chain and Manufacturing Capacity

Manufacturers like Sanofi Pasteur, GlaxoSmithKline, and Serum Institute of India produce IPV at scale. Recent investments increase global manufacturing capacity by approximately 35% since 2020, aiming to meet rising demand.

Population and Disease Burden

Global initiatives target vulnerable populations, especially in low- and middle-income countries. India's mass immunization campaigns and efforts in Nigeria and Pakistan bolster IPV uptake.

Challenges and Opportunities

Supply constraints during COVID-19 caused temporary shortages. The vaccine's high cost—approximately $2.50 per dose—limits access in some regions. However, initiatives like GAVI provide funding, expanding coverage.

What is the Revenue and Profit Outlook?

The compound annual growth rate forecasts revenues surpassing $1.5 billion by 2030. Profit margins are influenced by manufacturing costs exclusive of raw materials, regulatory expenses, and competition. Major players post gross margins of roughly 60%, while net margins stabilize around 25% after operational expenses.

Investment in R&D focuses on alternative formulations, such as fractional doses and thermostable versions, which could reduce logistics costs and expand markets.

Who Are Key Market Participants?

Company	Market Share (2022)	Notable Developments
Sanofi Pasteur	35%	Introduced fractional-dose IPV
GlaxoSmithKline	30%	Developed thermostable IPV
Serum Institute of India	20%	Low-cost IPV for emerging markets
Biological E. Ltd.	10%	Expanding manufacturing capacity

How Will Policy and Market Trends Shape Future Trajectory?

Polio Eradication Agenda

Global eradication initiatives aim for polio-free certification in many nations by 2026. The switch from OPV to IPV in routine immunization will sustain demand, especially in countries with logistical challenges.

Product Innovation

Innovations such as intradermal fractional dosing reduce the number of doses needed, lowering costs and increasing access. Thermostable IPV formulations facilitate vaccination in remote regions, potentially expanding market reach.

Market Expansion

Emerging markets with burgeoning populations and expanding healthcare infrastructure are key growth regions. GAVI's funding partnerships facilitate vaccine penetration in these areas.

Competitive Dynamics

Patent expirations and technology licensing may enable biosimilar development, intensifying price competition. Price pressures could compress margins, especially as manufacturing scale improves.

Key Financial Risks

• Manufacturing disruptions or raw material shortages can impair supply.
• Policy shifts toward OPV reintroduction could reduce IPV demand.
• Price pressures from biosimilars and generic producers may erode revenue streams.

Conclusion

The IPV market demonstrates steady growth, driven by global immunization policies, innovations in vaccine formulation, and expanding manufacturing capacity. Financial prospects remain positive, contingent on supply stability, regulatory approval of new formulations, and successful market expansion strategies.

---

Key Takeaways

• The global IPV market size was approximately $1.1 billion in 2022, with a projected CAGR of 4.8%.
• Major players include Sanofi Pasteur, GSK, Serum Institute of India, and Biological E.
• Demand remains strong due to polio eradication efforts, but challenges such as cost and supply disruptions persist.
• Innovations like fractional and thermostable IPV are expected to drive future growth.
• Policy shifts and competitive dynamics could influence market stability and profitability.

---

FAQs

1. What is the primary driver of IPV market growth?
   Global polio eradication initiatives and replacement of OPV in routine immunizations.

2. How are recent innovations impacting IPV deployment?
   Fractional doses and thermostable formulations reduce costs and logistical barriers.

3. Which regions represent the largest markets for IPV?
   North America, Europe, and Asia-Pacific lead in vaccination coverage and market share.

4. What are the main risks facing the IPV market?
   Supply chain disruptions, policy shifts favoring OPV, and biosimilar competition.

5. How does IPV market profitability compare among major manufacturers?
   Gross margins are around 60%, with net margins near 25%, though margins can fluctuate based on R&D and manufacturing investments.

---

References

[1] MarketsandMarkets, “Inactivated Poliovirus Vaccine Market,” 2023.
[2] WHO, “Poliovirus vaccines and immunization,” 2022.
[3] GAVI, “Vaccine introductions and funding,” 2023.
[4] Statista, “Global vaccine market size,” 2022.